Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Trump’s ‘most-favored nation’ drug pricing scheme faces lawsuits

By Brian Buntz | December 16, 2020

Image from Michael Longmire on Unsplash

Almost immediately after President Trump indicated he planned on tying Medicare reimbursement for dozens of drugs to lower rates in other countries, it seemed certain that legal action was inevitable.  

Now, Trump’s executive orders related to drug pricing are attracting a growing number of lawsuits. Earlier this month, the Pharmaceutical Research and Manufacturers of America (PhRMA), the Association of Community Cancer Centers (ACCC), the Global Colon Cancer Association (GCCA) and the National Infusion Center Association (NICA) filed a lawsuit in the U.S. District Court for the District of Maryland regarding the rule. 

The lawsuit demands urgent action to “stop a legally deficient, wholesale transformation of the Medicare program via interim final regulation that will cause immense, irreparable harm to patients, healthcare providers, and pharmaceutical manufacturers.”  

The Biotechnology Innovation Organization, California Life Sciences Association and Biocom California have filed a similar lawsuit in a California federal court suit. 

On Dec. 11, the Community Oncology Alliance and Regeneron Pharmaceuticals (NSDQ:REGN) also filed lawsuits in New York federal court and Washington, D.C., respectively. 

The drug-pricing scheme is set to go into effect on Jan. 1, 2021. 

The PhRMA-backed suit argues that CMS does not have the statutory authority to enforce the rule. The organization explained in a statement that the rule “raises serious constitutional questions and improperly fails to follow required rulemaking procedures.” 

The Community Oncology Alliance and Regeneron also maintain that the rule was finalized without proper notice and a public comment period described in the Administrative Procedure Act. 

CMS maintains in a document explaining the rule that the policy will “control unsustainable growth in Medicare Part B spending without adversely affecting quality of care for beneficiaries.”

Several of the organizations attempting to block enforcement of the rule argue otherwise. The Community Oncology Alliance, for instance, described the policy in its complaint as “a dangerous and unlawful gamble with the lives of some of America’s sickest and oldest cancer patients who require chemotherapy, immunotherapies, and other potentially life-saving drugs.” The group also maintains that the pricing scheme would force oncologists to “administer therapies that will be reimbursed at a rate that is significantly less than the cost of those therapies.” 

While President Trump has asserted that the pharmaceutical industry is “getting away with murder,” he has also extolled the industry’s promise in battling the COVID-19 pandemic. Trump has, for instance, described an antibody cocktail as a COVID-19 “cure.” He has also touted the vaccine from Pfizer (NYSE:PFE) and BioNTech (NSDQ:BNTX) as a “medical miracle.”  

 

 

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Moving toward the autonomous lab and what’s possible today
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
Genentech roche
Roche, Genentech to build $700M drug manufacturing plant in North Carolina
These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE